Eli Lilly Stock Surges on Weight-Loss Drug Trial Success

Eli Lilly & Co (NYSE:LLY) stock is headed for its best day since August 2023, last seen up 13.4% at $838.48 at last check, after the pharmaceutical giant reported positive results for a phase 3 trial of its weight-loss drug, orforglipron. The experimental pill resulted in weight loss of nearly 8% at the highest dose, and lowered blood sugar in patients with type 2 diabetes. Today's pop helped Eli Lilly stock fully recover from its early April bear gap, and has it back in positive territory for 2025. LLY was ...